摘要
Abstract
Objective: To determine the clinical effect of montelukast, a leukotriene receptor antagonist, in 5 to 14 year old children with asthma. Methods: A total of 84 children patients according to a randomized double-blind control study were divided into two groups. Patients were given montelukast (5 mg chewable tablet) or matching-image placebo once daily at bedtime for 4 weeks. Morning peak expiratory flow rate value (PEFam) , maximum peak flow vaIues in the evening (PEFpm) , first second forced expiratory volume (FEV1) , daytime and nocturnal asthma symptom score, cough score, night hold up days and the course of using beta 2 agonists in two groups were recorded. Results: In the treatment group, lung function indexes such as PEFam (356. 23 ± 11. 32) L/min, PEFpm (334, 32±12.34)L/min, FEV1 (1.64+0.78)L and FEV1/FVC (87.3±7.76)% was significantly better than those in the observation group (PEFam (323. 67±10. 32)l/min, PEFpm (298.32+11. 54)L/min, FEV1 (1. 23±0.56)L, FEV1/FVC (81.5±7.97)% . The difference was statistically significant (P<0.05). The daytime asthma symptom score, nocturnal asthma symptom score, cough score, night hold up days, and the course of using beta 2 agonists in treatment group were significantly lower than those in the control group, there were significant differences (P<0.01). Both groups of patients had no severe adverse reaction. Conclusions: Montelukast improves lung function in 5 to 14 year old children with chronic asthma.关键词
孟鲁司特/哮喘/儿童/肺功能Key words
Montelukast/Asthma/Children/Lung function分类
医药卫生
